ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT) from its SEC filings: 2025 revenue $44.3 billion (+6% vs the year before), net margin 15%, free cash flow $7.4 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $44.3 billion |
| Revenue growth | +6% |
| Net income | $6.5 billion |
| Net margin | 14.7% |
| Free cash flow | $7.4 billion |
| Diluted EPS | $3.72 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | +8% |
| Cash | $6.8 billion |
| Long-term debt | $29.6 billion |
| Share count, 1 year | +0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.